Posted by Michael Wonder on 27 Jun 2024
Ionis announces olezarsen FCS new drug application accepted for priority review
26 June 2024 - Olezarsen PDUFA date set for 19 December 2024 for treatment of familial chylomicronemia syndrome.
Ionis Pharmaceuticals today announced that the US FDA has accepted for priority review the new drug application for olezarsen, an investigational RNA targeted medicine for the treatment of adults with familial chylomicronemia syndrome.
